All News

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.

The use of IVIG in the treatment of recalcitrant pemphigus vulgaris and foliaceus and bullous pemphigoid is supported by 2 clinical trials.

It is important for health care providers to explain compliance to these regimens to patients, both from a clinical and cost perspective.

COVID-19 permanently changed how pharmacists recommend and sell nonprescription options.

Common precautions to prevent the spread of COVID-19 also decreased the rates of common respiratory illnesses in 2020 and early 2021.

Prescribers should be aware of new, second-generation antihistamines to manage hay fever and outbreaks of hives, according to a recent study.

Two studies in the 1990s identified gum bleeding as a biomarker for vitamin C levels, although this connection somehow disappeared in dental conversations around gum bleeding.

Clinicians can play an important role in counseling patients about the 5 main OTC categories of laxatives to treat this gastrointestinal condition.

Pharmacy Times has been a constant source of up-to-date, practical information for the pharmacy community and has led the way in presenting valuable information on the OTC market—in print and via online venues.

Since 1997, Pharmacy Times has been calculating pharmacists’ OTC recommendations and publishing an annual survey.

The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.

The development of precision medicine for pancreatic cancer has faced a number of challenges, including a lack of specific molecular-targeted drugs.

Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what is still needed to be investigated in the future following the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what some of the most important findings were in regard to patient outcomes from the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer.

Research pharmacist Brian Wortz, PharmD, with Cancer Treatment Centers of America, said working as a pharmacist in clinical research provides interesting opportunities to be at the forefront of drug development.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses findings regarding adverse events during the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses his presentation on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer.

Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.

Cabenuva, the first long-acting injectable for the treatment of HIV, is a 2-drug copackaged product containing cabotegravir and rilpivirine.

Study highlights the importance of developing solid relationships with patients, so they are comfortable asking questions and trust pharmacists with their care.

ibrutinib (Imbruvica) plus venetoclax (Venclexta) shows complete response and complete response with incomplete bone marrow recovery rate of 56% among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.